08:15 AM EDT, 06/30/2025 (MT Newswires) -- BridgeBio Pharma ( BBIO ) said Monday it has sold a part of its European royalty rights for Beyonttra to HealthCare Royalty and funds managed by Blue Owl Capital (OWL) for an upfront payment of $300 million.

Under the terms of the agreement, BridgeBio is selling 60% of its European royalties on the first $500 million in annual net sales of Beyonttra. Total payments to the investors are capped at 1.45x.

Acoramidis is approved as Attruby in the US and as Beyonttra in Europe, Japan and the UK.

BridgeBio said the "immediate less-dilutive capital" will strengthen its balance sheet and support the launch of Attruby and ongoing late-stage pipeline programs.